#United States #Milford #Waters Corporation #BD OneFlow #Blood Cancer Tests

Waters Corporation Achieves FDA Clearance for Groundbreaking Diagnostic Tests

In a significant stride for cancer diagnostics, Waters Corporation (NYSE: WAT) has announced that it has received FDA 510(k) clearance for the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test. This landmark approval empowers healthcare professionals in the U.S. to utilize standardized and ready-to-use flow cytometry tests specifically designed for identifying B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), offering critical support in the fight against these blood cancers.

The BD OneFlow tests deliver impressive diagnostics efficiency, featuring a sensitivity of 96.3% and specificity of 98.2% in identifying chronic lymphocytic leukemia, which stands as one of the most prevalent types of NHL. This significant advancement not only paves the way for quicker, reliable diagnostic insights but also greatly enhances the workflow efficiency by reducing manual testing steps by an impressive 95%.

Revolutionizing Flow Cytometry Diagnostics

Waters Corporation's development of the BD OneFlow solution represents an innovative integration of reagents, instruments, defined staining protocols, and assay templates into a cohesive workflow that streamlines immunophenotyping for both normal and abnormal cell populations. Dr. Alexandra Kovach, a Hematopathologist at Boston Children's Hospital, spoke on the traditional challenges faced by clinical flow cytometry, noting that the lab-specific approaches often led to inconsistencies. With standardized gating and analysis, the BD OneFlow tests promise greater reliability and reproducibility, vital in today's ever-evolving healthcare landscape.

The importance of these diagnostics is underscored by current estimates that project nearly 79,320 individuals in the U.S. will be diagnosed with NHL in 2026 alone, with approximately 22,760 cases classified as CLL. Tragically, CLL accounts for nearly 4,350 deaths per year, making the availability of accurate and standardized diagnostic solutions all the more critical.

Enhancing Diagnostic Accessibility

“Access to accurate, standardized testing is essential for pathologists and clinicians as they navigate the complexities of blood cancer diagnostics,” stated Steve Conly, Senior Vice President of Waters Biosciences. He emphasized that the FDA clearance marks a crucial milestone not only for the BD OneFlow tests but also for the entire line of flow cytometry diagnostics, aiming to reduce the variability often encountered in lab environments.

The BD OneFlow portfolio derives its foundation from collaborative efforts by the EuroFlow Consortium, a research initiative dedicated to producing rapid, highly sensitive flow cytometry tests for hematological malignancies. Beyond lymphoma and leukemia, this portfolio aims to include diagnostic tests for other blood cancers such as multiple myeloma, acute lymphoblastic leukemia, and acute myeloid leukemia, thus broadening the impact of the BD OneFlow initiative.

As the medical community anticipates the official launch of these innovative tests in the U.S. by Spring 2027, it allows for significant anticipation surrounding their potential accessibility to laboratories and patients alike. Preorders for the tests are already being accepted online, setting the stage for a new era in cancer diagnostics.

In conclusion, the FDA clearance granted to Waters Corporation for the BD OneFlow LST Test and BD OneFlow B-CLPD T1 Test signifies a pivotal achievement in the realm of oncological diagnostics, providing the tools necessary for prompt and reliable identification of blood cancers. With a commitment to innovation and excellence in scientific endeavors, Waters continues to pave the way towards improving patient outcomes worldwide.

For further insights into these newly cleared diagnostic tests, interested parties can visit BD Biosciences.